Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for neoadjuvant therapy and pembrolizumab versus placebo for adjuvant therapy in triple-negative breast cancer
2016-004740-11Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Pembrolizumab plus chemotherapy then pembrolizumab with Placebo plus chemotherapy then placebo (2 arms). Primary endpoints: Pathological complete response rate (ypT0/Tis ypN0) and Overall survival. Started Jan 2017; status: active.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-004740-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004740-11.